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Edited by Vladimir SkulachevAbstract In the present study, we have examined the potential
ability of 50-AMP-activated protein kinase (AMPK) to modulate
NADPH oxidase activity in human neutrophils. AMPK acti-
vated with either 50-aminoimidazole-4-carboxamide ribonucleo-
side (AICAR) or with 50-AMP signiﬁcantly attenuated both
phorbol 12-myristate 13-acetate (PMA) and formyl methionyl
leucyl phenylalanine-stimulated superoxide anion ðO2 Þ release
by human neutrophils, consistently with a reduced translocation
to the cell membrane and phosphorylation of a cytosolic
component of NADPH oxidase, namely p47phox. AMPK was
found to be present in human neutrophils and to become
phosphorylated in response to either AICAR or other stimulators
of its enzyme activity. Furthermore, AICAR also strongly
reduced PMA-dependent H2O2 release, and induced the phos-
phorylation of c-jun N-terminal kinase 1 (p46), p38 mitogen-
activated protein kinase and extracellular signal-regulated
kinase. Present data demonstrate for the ﬁrst time that the
activation of AMPK, in states of low cellular energy charge
(such as under high levels of 50-AMP) or other signals, could be a
factor contributing to reduce the host defense mechanisms.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Upon interaction with phagocytic stimuli, neutrophils ex-
hibit an increase in oxygen consumption and in hexose
monophosphate shunt activity. Concomitantly, neutrophils* Corresponding author. Fax: +34-954907041.
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doi:10.1016/j.febslet.2004.07.077produce and secrete reactive oxygen species, such as superox-
ide anion ðO2 Þ, hydrogen peroxide (H2O2) and singlet oxygen,
which are important for the eﬃcient killing of ingested mi-
croorganisms [1,2], and which may well be implicated in tissue
damage in inﬂammation-mediated diseases. All of these
changes are secondary to the activation of a membrane-bound
NADPH oxidase, the enzyme responsible for O2 production
[3]. Phagocytic NADPH oxidase is a very complex enzyme,
composed of at least seven subunits: a membrane-bound
component, cytochrome b558 (a heterodimer comprising the
gp91phox and p22phox subunits), and the cytosolic proteins
p47phox, p67phox, p40phox, rac and Rap-lA. The p47phox and
p67phox polypeptides, together with the cytosolic p40phox com-
ponent, translocate in the plasma membrane to reconstitute the
active enzyme upon cell activation [4,5]. Rap-1A has been
shown to speciﬁcally bind to cytochrome b558, and to become
phosphorylated by the cAMP-dependent kinase protein kinase
A (PKA) [6], which abrogates its interaction with cytochrome
b558 [7] leading to the deactivation of NADPH oxidase [8].
This oxidase can be activated either by receptor-mediated sig-
naling processes (e.g., those initiated by complement fragment
C5a and the chemotactic tripeptide N-formyl-Met-Leu-Phe
(fMLP)) [9], or by receptor-independent mechanisms (e.g., in
response to long-chain unsaturated fatty acids or phorbol
12-myristate 13-acetate (PMA)) [10].
On the other hand, an energy-signaling protein has been
described, the AMP-activated protein kinase (AMPK) [11],
which is present in muscle and liver, as well as in macrophages
and other tissues [12]. This enzyme appears to play a key role
in regulating energy homeostasis in eukaryotes. Intracellular
50-AMP activates AMPK via several distinct mechanisms: (i)
50-AMP causes a direct allosteric activation of AMPK [13]; (ii)
binding of 50-AMP to AMPK renders it a better substrate for
the upstream AMPK kinase (AMPKK/LKB1), or a worse
substrate for protein phosphatases [13–15]; and (iii), the up-
stream kinase AMPKK/LKBl, which is also allosterically
stimulated by 50-AMP, in turn phosphorylates and activates
AMPK [14,15]. AMPK also modulates positively other ATP-
generating pathways, such as glycolysis [16] and fatty acid
oxidation [17]. It has been shown that an adenosine analog, 5-
aminoimidazole-4-carboxamide 1-b-D-ribofuranoside (AI-
CAR), which enters cells and is phosphorylated by adenosineblished by Elsevier B.V. All rights reserved.
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stimulator of AMPK [16,18], and also an intermediate in the
purine de novo synthesis pathway.
On the other hand, adenine nucleotides, such as ATP, have
been shown to stimulate adhesive functions in neutrophils [19].
However, conﬂicting results have been reported regarding the
activation of the respiratory burst in neutrophils after treat-
ment with adenine nucleotides. Thus, O2 release has been
found to become unaﬀected [19], decreased [20], or enhanced
[21] when compared with untreated human neutrophils. A
requirement of extra energy to provide NADPH as a substrate
for the oxidase reaction during phagocytosis has also been
accepted [22], since a signiﬁcant enhancement of glycogen
degradation, glucose utilization and lactate production was
observed under these conditions [23,24]. Since it is known that
endogenous levels of ATP are depleted during phagocytosis
[25], the purpose of the present study was, therefore, to eval-
uate the potential role of 50-AMP-stimulated kinase (AMPK)
on the respiratory burst in human neutrophils and to shed
some light on the speciﬁc signaling pathways involved.2. Materials and methods
2.1. Reagents
Dextran T-500 and Ficoll-Paque were obtained from Amersham-
Pharmacia-Biotech (Barcelona, Spain). PMA, cytochrome c, horse-
radish peroxidase (HRP)-conjugated rabbit anti-goat, goat anti-rabbit
and goat anti-mouse immunoglobulin G (IgG), 5-aminoimidazole-4
carboxamide-riboside (AICAR), scopoletin, N-formyl-L-methionyl-L-
leucyl-L-phenylalanine (fMLP), 8-bromoadenosine 50-monophosphate
(8-BrAMP), rotenone, 2,4-dinitrophenol (DNP), 4-iodophenol and
bovine serum albumin (BSA) were obtained from Sigma Chemical Co.
(Madrid, Spain). A goat antiserum raised against p47phox was kindly
donated by Dr. T. Leto (National Institutes of Health, Bethesda, MD)
[26]. Luminol (5-amino-2,3-dihydrophthalazine-l,4-dione) was pur-
chased from Serva Feinbiochemica GmbH (Madrid, Spain). PVDF
membranes were purchased from Bio-Rad (Hercules, CA). Xanthine
oxidase and xanthine were purchased from Roche Diagnostics (Bar-
celona, Spain). Rabbit polyclonal anti-phospho-mitogen-activated
protein kinase (p38MAPK) (Thr180/Tyr182) and anti-phospho-extra-
cellular signal-regulated kinase (ERK)1/2 (Thr202/Tyr204) and anti-
bodies against their unphosphorylated counterparts speciﬁc antibodies
were obtained from New England Biolabs (Beverly, MA). Mouse
monoclonal anti-phospho-c-jun N-terminal kinase (JNK)l/2 (Thr183/
Tyr185) (sc-6254) and anti-bactin antibodies were from Santa Cruz
Biotechnology (Santa Cruz, CA).
2.2. Preparation of human neutrophils
Human peripheral neutrophils were obtained from healthy blood
donors, following their informed consent. Neutrophils were isolated
from fresh heparinized blood as described [27]. Neutrophils (107 cells/
ml) were resuspended in RPMI medium supplemented with 10% fetal
bovine serum plus 2 mM L-glutamine, 100 U/ml penicillin and 100 lg/
ml streptomycin or, where indicated, in HEPES-buﬀered Krebs–
Ringer solution (KR–HEPES), and subjected to the drug treatments
indicated in each case, washed twice with ice-cold KR–HEPES and
immediately lysed.
2.3. Western blotting
Human neutrophils (107 cells/ml) were lysed by sonication on ice (20
W, three bursts of 5 s each separated by 30 s intervals) in 50 ll of a
buﬀer containing Tris/HCl (50 mM), pH 7.5, NaF (50 mM), sodium
pyrophosphate (5 mM), dithiothreitol (1 mM), glycerol (10%, v/v),
Triton X-100 (1%, v/v), and the protease inhibitors PMSF (1 mM),
leupeptin, aprotinin (10 mg/ml each) and benzamidine (156 lg/ml).
The homogenate was centrifuged at 15 000 g for 10 min at 4 C.
Proteins extracts in the cell supernatant were separated by SDS–PAGE
on 7.5% (w/v) polyacrylamide gels and transferred to PVDF mem-
branes using a semi-dry device (Bio-Rad, Richmond, USA) [27]. Themembranes were probed with speciﬁc antibodies against phospho-
AMPK (Cell Signaling Technology) (1:1000 dilution) in phosphate
buﬀer saline (PBS) containing BSA (1%) and Tween 20 (0.2%), at 4 C
overnight, and after washing with PBS the membrane was incubated
with HRP-conjugated goat anti-rabbit IgG, followed by enhanced
chemiluminescence [27,28]. For the detection of p38MAPK, ERK1/2
and JNK1/2 phosphorylation was carried out as in [29].
2.4. O2 production
Superoxide production was measured on the basis of the cytochrome
c method [30], which is highly speciﬁc for O2 released to the extra-
cellular medium, given the inability of citochrome c to permeate
through the plasma membrane [31]. Neutrophils (106 cells/ml) were
preincubated for 20–30 min with or without AICAR in KR–HEPES,
and cytochrome c (80 lM) reduction was measured spectrophoto-
metrically following the method previously described [32]. For the
measurement of ROS production, neutrophils (106 cells/ml) were sus-
pended in KR–HEPES buﬀer and preincubated at 37 C for 20 min
with the compounds indicated in each case. Then, luminol (20 lM) and
HRP (8 mU/ml) were added, and the assay was carried out as indicated
previously [33]. The reaction was started by the addition of PMA to
the cellular suspension, and chemiluminescence emission was recorded
at diﬀerent times using a Wallac 1420 Victor2 (Perkin–Elmer) lumi-
nometer.
2.5. Extracellular levels of H2O2
Hydrogen peroxide production was measured by a modiﬁcation of
the scopoletin oxidation assay, as in [34]. Brieﬂy, neutrophils were
suspended in 300 ll of RPMI 1640 medium (1.5 106 cells/well)
containing 10% fetal bovine serum and incubated with the indicated
drugs for the indicated times. Then, HRP (2.4 U/ml), NaN3 (1 mM) (to
inhibit myeloperoxidase and catalase activities) and scopoletin (3 lM)
were added. The production of H2O2 was triggered upon PMA addi-
tion, and the ﬂuorescence intensity was measured for 20 min in the
Wallac 1420 Victor2 spectroﬂuorometer, using excitation and emission
wavelengths of 355 and 460 nm, respectively.
2.6. Superoxide dismutase and glutathione peroxidase activity
Superoxide dismutase (SOD) activity was determined by measuring
the inhibition of cytochrome c reduction by the xanthine–xanthine
oxidase system [30]. This enzyme activity was measured in extracts of
neutrophils previously chromatographied through a Sephadex (G25)
column in order to remove small molecules. Glutathione peroxidase
activity was assayed using a coupled enzyme system [35].
2.7. Mobilization of p47phox
The neutrophil plasma membrane fraction was prepared as previ-
ously reported [27] and subjected to SDS–PAGE and electroblotted
onto PVDF membranes as indicated above. Antibody probing was
carried out overnight without the need for prior blocking [36] with goat
anti-p47phox IgG (1:1000 dilution) in PBS containing BSA (1%) and
Tween 20 (0.02%). Antibody binding was detected as indicated above.
For immunoprecipitation experiments, incubation with anti-p47phox
speciﬁc antibodies and subsequent procedure were carried out as in-
dicated [28].
2.8. RT-PCR analysis of AMPK mRNA levels
Total cellular RNA was extracted using the phenolguanidinium
isothiocyanate method [37]. Reverse transcription to cDNA was per-
formed at 37 C for 1 h in 24 ll of a reaction mixture containing 2 lg
of RNA, the 4 dNTPs (1 mM each), 2.5 lM random hexamer primers,
1 mM DTT, 20 U of RNasin ribonuclease inhibitor and 100 U of M-
MLV reverse transcriptase (Promega, Madison, WI). PCR ampliﬁca-
tion of cDNA was performed in 10 ll of reaction using the following
AMPK-a (GenBank Accession No. 206907) speciﬁc primers at 0.5 lM
each: forward, 50-GTCGGCGTCTGTTCCAACAGA-30; reverse, 50-
CCCTCTTCATGGGATCCACCT-30, the 4 dNTPs (400 lM each),
5% DMSO and 1 U of Taq DNA polymerase (Roche Diagnostics,
Barcelona, Spain). After an initial denaturation step at 95 C for 5 min,
PCR was performed for a total of 35 cycles, each of 95 C for 1 min, 60
C for 1 min, and 72 C for 1 min. To ensure that equal amounts of
cDNA were added to PCRs, the glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) gene was ampliﬁed as a control, using the following
primers: forward, 50-CCACCCATGGCAAATTCCATGGC-30; re-
verse, 50-TCTAGACGGCAGGTCAGGTCCACC-30. PCR-ampliﬁed
Fig. 1. AICAR and rotenone promote AMPK phosphorylation and
induce AMPK-a mRNA expression. (A) Neutrophils (107 cells/ml)
were resuspended in RPMI and then incubated in the absence or
presence of AICAR (1 mM) or rotenone (3 lM) at 37 C for 1 h. The
cells were then lysed and proteins were separated electrophoretically,
transferred to PVDF membranes and probed with anti-phospho-
AMPK. The blot shown is representative of a set of three experiments
that yielded similar results. (B) Neutrophils isolated from four healthy
individuals (1–4) were lysed, and AMPK-a and GAPDHmRNA levels
were analyzed by RT-PCR.
Fig. 2. AICAR, DNP and rotenone inhibit PMA-dependent ROS productio
pended in KR–HEPES buﬀer and then preincubated with or without AICAR
reaction was started by the addition of (A) PMA (100 nM) or (B) fMLP (100 n
by the change in cytochrome c absorbance at 550 nm. (C) Neutrophils (106 ce
presence of DNP (0.5 mM) for 10 min. PMA (50 nM) was then added (arro
chemiluminescence. (D) Neutrophils (106 cells/ml) were suspended in KR–HE
rotenone (3 lM) at 37 C for 10 min, and then O2 production was analyzed
diﬀerent experiments.
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mide using the BioDoe-ItTM system (UVP, Upland, CA).3. Results
In the present work, we have studied the potential ability of
AICAR to modulate O2 and H2O2 production by phagocytic
cells. As indicated previously, AICAR stimulates the phos-
phorylation and activation of AMPK [18]. Initial experiments
were designed to analyze whether AMPK was present in hu-
man neutrophils. Fig. 1A illustrates that the enzyme became
phosphorylated, and hence stimulated, when neutrophils were
treated with AICAR or rotenone. Moreover, Fig. 1B shows
that the mRNA of the AMPK-a subunit was expressed in
human neutrophils from four healthy unrelated individuals.
Subsequent experiments were addressed to study whether O2
production was altered by AICAR and/or by other reagents
able to activate AMPK, such as DNP and rotenone. Fig. 2
illustrates that in neutrophils treated with AICAR for 30 min,
both PMA-dependent (A) and fMLP-dependent (B) release of
O2 became partially inhibited. This AICAR negative eﬀect
was progressive and attained its maximal value at about 10
min after PMA addition. However, AICAR inhibition was
maintained after this time in fMLP-stimulated cells (B). Wen in human neutrophils. (A, B) Neutrophils (106 cells/ml) were resus-
(1 mM) at 37 C for 30 min. Cytochrome c (80 lM) was added and the
M) as indicated (arrow). The extracellular release of O2 was measured
lls/ml) were incubated in KR–HEPES buﬀer at 37 C in the absence or
w) and ROS production was analyzed on the basis of luminol-derived
PES buﬀer and then preincubated with or without DNP (0.5 mM) or
as in panels A and B. Data are expressed as meansS.E.M. of three
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O2 production system (xanthine/xanthine oxidase, data not
shown) Fig. 2 also shows that DNP or rotenone treatment
clearly reduced both PMA-dependent ROS (C) and O2 (D)
production.
Furthermore, other respiratory chain uncouplers, such as
oligomycin, antinomyin A and FCCP, exerted a similar in-
hibitory eﬀect on ROS production by PMA-stimulated human
neutrophils (data not shown).
It must be noticed that the inhibitory eﬀect of AICAR re-
quired a previous time of cell pretreatment, since no inhibition
was found when AICAR was added simultaneously to PMA
(Fig. 3A). Preincubation with AICAR could be necessary to
activate AMPK before PMA is able to trigger the potent and
rapid phosphorylation of NADPH-oxidase components [1,38].
We show that a progressively increased preincubation time of
neutrophils with AICAR resulted in a 35% inhibition of O2
release after 1 h of treatment (Fig. 3A, inset).
The inhibitory eﬀect of AICAR on O2 release was dose-
dependent (Fig. 3B) and reached its maximal value at 1 mM.
Any concentration greater than this did not further enhance
the degree of observed inhibition (data not shown). Fig. 3B
illustrates that the negative eﬀect of AICAR was speciﬁcally
exerted through AMPK activation, since its inhibitory action
was partially reverted by previous treatment with 8-BrAMP,
an inhibitor of AMPK activity [12].
To analyze whether AICAR exerted also an eﬀect on ex-
tracellular H2O2 release, neutrophils were stimulated withFig. 3. AICAR inhibits O2 extracellular production in a dose- and time-depen
(A, B) Neutrophils (106 cells/ml) were resuspended in KR–HEPES buﬀer and
the indicated times, or (B) preincubated with diﬀerent concentrations of AICA
was started by the addition of PMA (100 nM, arrow). The change of cyto
(1.5 106 cells/ml) were resuspended in RPMI at 37 C, and then preincuba
mM) for 30 min. Then, NaN3 (1 mM), HRP (8.5 U/ml) and scopoletin (3
measured on the basis of ﬂuorescence intensity for 20 min in a Wallac 1420 Vi
separate experiments.PMA after preincubation in the absence or presence of AI-
CAR for 30 min. Fig. 3C illustrates that AICAR treatment
inhibited by about 70% PMA-dependent H2O2 release, and
that this eﬀect was reversed to a 50% inhibition by 8-BrAMP.
Since potential source of H2O2 is O

2 dismutation through
the SOD enzyme activity, in order to explain the diﬀerent
rates of inhibition exerted by AICAR on O2 and H2O2
production, we set to measure SOD activity. Experiments
were performed using extracts of human neutrophils which
were incubated with either AICAR or 50-AMP at 37 C for 30
min, and SOD activity levels measured (in U/mg protein)
were 1.49 0.19 in untreated extracts, 0.98 0.12 with 1 mM
AICAR and 1.18 0.12 with 1 mM AMP. Thus, both AI-
CAR or 50-AMP inhibited SOD activity by 34% and 22%,
respectively. Since another enzyme potentially able to remove
H2O2 is glutathione peroxidase, we also set to analyze its
activity in order to explain the AICAR eﬀect. Glutathione
peroxidase activity was found to become increased after AI-
CAR treatment of neutrophils to 5.1 0.15 U/mg protein, as
compared to levels measured in untreated neutrophils
(3.9 0.17 U/mg protein). In summary, the observed low
levels of H2O2 release after AICAR treatment could be a
consequence of the additive eﬀects of AICAR on three con-
secutive acting enzyme systems (i.e., NADPH oxidase, SOD
and glutathione peroxidase).
Further experiments were addressed to analyze the eﬀect of
AICAR on the translocation to the plasma membrane of a
cytosolic component of NADPH-oxidase, p47phox, which isdent manner and H2O2 release in PMA-stimulated human neutrophils.
then (A) preincubated in the absence or presence of AICAR (1 mM) for
R for 1 h at 37 C. Cytochrome c (80 lM) was added and the reaction
chrome c absorbance at 550 nm was then recorded. (C) Neutrophils
ted with 8Br-AMP (1.5 mM) for 45 min, and further with AICAR (1
lM) were added and the production of H2O2 triggered by PMA was
ctor2 spectroﬂuorometer. Data are expressed as meansS.E.M. of four
Fig. 5. AICAR induces JNK phosphorylation and potentiates PMA-
and fMLP-induced p38 and ERK phosphorylation. Neutrophils (107
cells/ml) were resuspended in RPMI and preincubated with AICAR (1
mM) for 1 h, and then treated with PMA (100 nM) or fMLP (100 nM)
for 10 min, as indicated. Cells were lysed, proteins were separated
electrophoretically, transferred to a PVDF membrane and probed with
anti-phospho-JNK1/2 (A), p38MAPK (B), and ERK1/2 (C). To verify
even protein loading, the blots were subsequently stripped and rep-
robed with anti-b-actin, anti-p38MAPK and anti-ERKl/2 as shown.
Each blot is representative of a set of 3 experiments yielding similar
results.
Fig. 4. Translocation of p47phox to the plasma membrane (A) and its
phosphorylation (B) in stimulated human neutrophils are inhibited by
AICAR. Neutrophils (107 cells/ml) were preincubated with 8-Br-AMP
(2 mM) where indicated for 45 min and then with AICAR (1 mM) for
30 min at 37 C. Thereafter, the cells were treated with PMA (100 nM)
(A) and PMA (100 nM) or fMLP (100 nM) (B). (A) Plasma-membrane
fractions were separated electrophoretically and transferred to a
PVDF membrane, which was then probed with anti-p47phox antiserum,
and the reactive bands detected by luminol-enhanced chemilumines-
cence. Relative p47phox levels were determined by scanning densitom-
etry analysis using the Scion Image software. (B) The cells were lysed
and immunoprecipitation was carried out as indicated in Section 2.
The blots are representatives of a set of three experiments yielding
similar results.
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reduce the PMA-stimulated p47phox translocation in a dose-
dependent manner (Fig. 4A). This AICAR eﬀect was partially
prevented by previous treatment with 8-BrAMP. However,
neither AICAR nor 8-BrAMP exerted by itself any eﬀect on
p47phox mobilization. The phosphorylation of p47phox has been
implicated in the process of activation of NADPH oxidase,
during which the p47phox subunit is extensively phosphorylated
at 8–9 C-terminal serine residues [39]. In particular, the
phosphorylation of S379 is necessary for both translocation of
p47phox and activation of the oxidase [40]. Therefore, we set to
analyse the levels of p47phox phosphorylation in serine residues.
By means of immunoprecipitation experiment, we found that
AICAR treatment signiﬁcantly decreased p47phox serine
phosphorylation levels in both PMA- and fMLP-stimulated
neutrophils (Fig. 4B).
With regard to the signal-transducing molecules involved in
the AICAR inhibitory eﬀect on AMPK-dependent ROS pro-
duction, the relationship between NADPH oxidase and
MAPK activation is well known [39]. It has been described
that ERK and p38 MAPK phosphorylate p47phox in human
neutrophils [41] and that inhibitors of these kinases attenuate
the neutrophil respiratory burst stimulated by a wide array of
agonists [42,43]. Moreover, our group has shown that angio-
tensin II-dependent O2 production becomes suppressed by
speciﬁc inhibitors of the p38MAPK and ERK1/2 pathways
[29]. In the present work, we found that JNK1 becomes
phosphorylated upon AICAR treatment in human neutrophils
(Fig. 5A). Moreover, this compound was able to enhance
PMA-dependent phosphorylation of JNK1, although with noobservable change in JNK2 phosphorylation. We also found
that AICAR increased both PMA- and fMLP-dependent ef-
fects on p38MAPK phosphorylation, although AICAR ex-
erted no eﬀect by itself (Fig. 5B). A similar enhancing eﬀect of
AICAR on PMA-dependent ERK1/2 phosphorylation was
also found (Fig. 5C).
Recently, we have reported that PD98059 and SB203580
inhibit angiotensin II-dependent ROS production [29] by hu-
man neutrophils. However, in the present work we observed
that these MAPK inhibitors neither had any eﬀect on the
PMA-dependent ROS or H2O2 production (data not shown),
nor did they aﬀect the inhibitory eﬀect of AICAR on these
processes. These data suggested that AICAR inhibition of
ROS and H2O2 production is exerted by mechanisms inde-
pendent of MAPK activation.4. Discussion
AMP-activated protein kinase is a downstream component
of a protein kinase cascade acting as an intracellular energy
sensor and responsible for maintaining the energy balance
within the cell. Once activated, AMPK phosphorylates several
downstream substrates, the overall eﬀect of which is that ATP-
consuming pathways are switched oﬀ and ATP-generating
pathways are switched on [15]. Although the participation of
activated-AMPK in energy processes has been described, its
potential interaction with an energy-consuming system, such
224 G. Alba et al. / FEBS Letters 573 (2004) 219–225as the neutrophil NADPH oxidase, had not been previously
investigated. Present data illustrate that AMPK is located in
the cytosol of human neutrophils and that becomes phos-
phorylated, and hence activated, upon AICAR or rotenone
treatment. Moreover, the catalytic subunit of AMPK present
in neutrophils is the AMPK-a. In this paper, we describe that
the activation of AMPK promoted a decrease in the levels of
total ROS, and speciﬁcally of O2 and H2O2 release. These
observations were in agreement with the fact that other com-
pounds known to set as respiratory-chain inhibitors, such as
oligomycin, antinomycin A and FCCP, also inhibited ROS
production in neutrophils. We also found that AICAR in-
hibited both PMA- and fMLP-elicited O2 production, this
suggesting that AICAR could act at some common step of the
signaling pathways triggered by PMA and fMLP. The inhibi-
tion of both O2 and ROS production by AICAR ran parallel
to the translocation to the plasma membrane and phosphor-
ylation in serine residues of the p47phox subunit NADPH ox-
idase, which represent pivotal steps in the activation of this
enzyme [4,5]. The speciﬁc participation of AMPK on NADPH
oxidase inhibition was demonstrated by the fact that AICAR-
dependent inhibition of O2 production was canceled by 8-
BrAMP, which acts as an inhibitor of AMPK. There is the
possibility that an increase of 50-AMP could enhance intra-
cellular adenosine levels, a nucleotide previously shown to
strongly inhibit ROS production by neutrophils when these are
stimulated by fMLP, but not by PMA [44]. However, we here
show that AMPK activation by 50-AMP/AICAR inhibited
ROS production in cells stimulated by either fMLP or PMA.
Therefore, the observed inhibition by AICAR of NADPH
oxidase activity is unlikely to be exerted by adenosine itself.
The functional signiﬁcance of present ﬁndings could be that
the inhibition of NADPH oxidase, in a status of low energy
charge (i.e. high 50-AMP levels), could contribute to save ATP.
Early reports on phagocytic cells have reported an enhanced
requirement of energy when these become activated during
phagocytosis, or by treatment with PMA and lipopolysac-
charides [23]. It is known that endogenous levels of ATP are
depleted during phagocytosis [23,25], and hence the require-
ment of extra energy to provide NADPH as a substrate for the
oxidase reaction during phagocytosis could be provided by an
enhancement of glycogen degradation and glucose oxidation
through glycolysis [23]. We have reported that activated peri-
toneal macrophages from Escherichia coli-treated rats showed
an enhanced glycolytic rate, as measured on the basis of
fructose 2,6-bisphosphate levels, a stimulator of this metabolic
pathway, as well as by lactate production [45]. Moreover, the
response to PMA of key glycolytic enzymes, such as 6-
phosphofructo-1-kinase and 6-phosphofructo-2-kinase, was
greater in activated macrophages as compared to resting
macrophages from untreated animals [45]. It has been previ-
ously shown that AMPK is able to detect an increase of 50-
AMP intracellular levels and then enhances the cells capacity
to produce ATP [15]. In this regard, it has been recently
demonstrated that monocytes treated with lipopolysaccharides
show increased fructose 2,6-bisphosphate levels, and that the
activation of these cells by diﬀerent stimuli required the acti-
vation of 6-phosphofructo-2-kinase by AMPK [16].
In summary, AMPK likely acts as an intracellular energy
sensor responsible for maintaining the intracellular energy
balance by activating those processes leading to ATP synthesis
(e.g., glycolysis) and by reducing ATP-consuming reactions(e.g., O2 production). Additionally, present data suggest that
the activation of AMPK in states of low cellular energy charge
is an additional factor in the modulation of the host defense
mechanisms that become triggered upon O2 release by
phagocytic cells.
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